Abstract In the present study, we evaluated the ability of 4-hydroxytamoxifen (OHT) and epidermal growth factor (EGF) to regulate homotypic adhesion in MCF7 breast cancer cells. Our results demonstrate that OHT and EGF activate the E-cadherin promoter, increase E-cadherin mRNA and protein expression and enhance homotypic aggregation of MCF7 cells. Interestingly, an ERa and EGFR cross-talk is involved in the E-cadherin expression by OHT and EGF, as demonstrated by knocking down either receptor. On the basis of our findings, the wellestablished cross-talk between ERa and EGFR could be extended to the modulation of E-cadherin expression by OHT and EGF. Thus, the potential ability of tamoxifen to induce cell-cell aggregation may contribute to the biologic response of pharmacologic intervention in patients with breast cancer.
Introduction
Breast cancer is the most common malignancy in women worldwide with over one million cases diagnosed each year [1] [2] [3] . Estrogen is required for normal proliferation and differentiation of breast epithelial cells and is implicated in the development and progression of breast cancer [4] . The classical mechanism of estrogen action mainly involves two members of the nuclear receptor superfamily, the estrogen receptor (ER) a and ERb [5] . Steroid receptors, including ERa, have two main transcriptional activation functions named AF1 and AF2, which are associated with the N-terminal and the hormone-binding domains, respectively. Agonists of ERa induce a conformational change in the hormone-binding pocket that allows the recruitment of coactivators, which in turn maximize the transcriptional response to ligands [6] . Antagonists of ERs bind to the hormone-binding pocket; however, they block the AF2 in an inactive conformation. In addition, ERa can be activated by a host of extracellular signals, including growth factors, in the absence of the cognate ligand 17b-estradiol (E 2 ) [7] [8] [9] . Of interest, partial antagonists of ERa, such as 4-hydroxytamoxifen (OHT), may display cell-and promoter-specific agonist effects that are thought to be due, at least in part, to AF1 activity and/or to the ability to recruit cofactors [10] [11] [12] . OHT was the first antiestrogen approved for the clinical management of ER-positive breast cancers and has been recommended as first-line treatment for the past three decades [4] . Despite the beneficial effects of OHT for patients at all stages of ER-positive breast cancer [13] , the major obstacle to its use is the development of tamoxifen resistance, which either occurs de novo or in patients showing initial benefits [14] . Growth factors, including EGF, are involved in breast cancer progression [15, 16] . Binding of EGF to the cognate receptor EGFR initiates a transduction cascade with sequential phosphorylation and activation of a series of intracellular signaling molecules. Among the downstream pathways activated by EGF, it is important to mention the cell survival cascade mediated by PI3-kinase (PI3-K) and AKT/PKB [17, 18] , the cell proliferation pathway mediated by the mitogenactivated protein kinases (MAPK) ERK1/2 [19, 20] and the stress-induced pathways mediated by the stress-activated protein kinase/JNK and p38 MAPKs [21] . On the other hand, rapid E 2 stimulation through ERa also activates these transduction pathways, which synergistically trigger cell survival and proliferation [22, 23] . In addition, ERa can be promptly activated in a ligand-independent manner by EGF, which mimics E 2 in inducing agonist effects including breast cancer cell growth [24] [25] [26] .
In the epithelium and in epithelium-derived tumors, cell-cell adhesion and tumor mass mostly rely on functions of E-cadherin, which is an intercellular adhesion molecule generally considered as a tumor suppressor [27, 28] . Alteration in the activity of E-cadherin and the cadherincatenin complex has been implicated in cancer progression [29] , invasion [30] [31] [32] and metastasis [33, 34] . Considering that in our recent study, ERa-mediated homotypic tumor cell adhesion was induced by E 2 through an increase in E-cadherin expression [35] . In the present investigation, we evaluated whether the mixed ER agonist/antagonist OHT and the well-known ERa activator EGF could mimic the aforementioned action of E 2 in MCF7 breast cancer cells.
Materials and methods

Plasmids
The plasmid containing the human E-cadherin promoter (-p1008/?49) was obtained from Dr. Y. S. Chang (ChangGung University, Republic of China) [36] .
Cell lines and culture conditions MCF7 cells were grown in DMEM/F-12 containing 10% FBS supplemented with 1% L-glutamine and 1% penicillin/ streptomycin (Sigma, Milan, Italy). Cells were switched to medium without serum 48 h before RT-PCR, immunoblots, and evaluation of ERK1/2 phosphorylation.
Transfections and luciferase assays MCF7 cells were plated onto 24-well dishes with 500 ll regular growth medium/well the day before transfection. The medium was replaced with the lacking serum on the day of transfection, which was performed using FuGene6 reagent as recommended by the manufacturer (Roche Diagnostics, Milan, Italy) with a mixture containing 0.5 lg reporter plasmid and 2 ng pRL-thymidine kinase. After 24 h, we renewed the serum-free medium containing the indicated treatment, and then cells were incubated for approximately 16 h. Luciferase activity was measured with the dual luciferase kit (Promega Italia, Milan, Italy) according to the manufacturer's recommendations. Firefly luciferase values were normalized to the internal transfection control provided by the Renilla luciferase activity. The data are reported as normalized relative light unit (RLU) values.
RT-PCR
The evaluation of gene expression was performed by semiquantitative RT-PCR, as we have previously described [37] . For E-cadherin, pS2 and the acidic ribosomal phosphoprotein P0 (36B4), which was used as a control gene, the primers were, respectively, 5
0 (36B4 forward) and 5 0 -CA AATCCCATATCCTCGTCC-3 0 (36B4 reverse) to yield products of 285, 210 and 408 bp, respectively, with 20, 15 and 15 PCR cycles.
Western blotting
Equal amounts of whole protein extract were resolved on a 8-10% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane (GE Healthcare, Milan, Italy), probed overnight at 4°C with the antibodies against E-cadherin, EGFR, b-actin (Santa Cruz Biotechnology, Milan, Italy), pERK1/2 and total ERK (Cell Signaling Technology and Celbio, Milan, Italy) and then revealed using the enhanced chemiluminescence system (GE Healthcare).
ERa, EGFR and Sp1 silencing experiments
Cells were plated onto 10-cm dishes, maintained in antibiotic-free medium for 24 h and then transfected for additional 24 h before treatment with a mixture containing Opti-MEM, 8 ll/well LipofectAMINE 2000 (Invitrogen, Milan, Italy), 0.5 lg/well control siRNA or ERa siRNA (Sigma), vector or shEGFR purchased from SuperArray (Bioscience Corporation, Frederick, MD) and 200 nM/well of control siRNA or Sp1 siRNA (Applied Biosystems, Milan, Italy).
Chromatin immunoprecipitation (ChIP) assay MCF7 cells were treated with 1 lM OHT or 100 ng/ml EGF for 1 h. Thereafter, cells were cross-linked with 1% formaldehyde and sonicated. Supernatants were immunocleared with salmon DNA/protein A agarose (Upstate Biotechnology, Lake Placid, NY) and immunoprecipitated with anti-ERa antibody or with anti-RNA Pol II (Santa Cruz Biotechnology). Pellets were washed as reported [38] , eluted with elution buffer and digested with proteinase K. DNA was obtained by phenol/chloroform extraction and precipitated with ethanol; 3 ll of each sample was used for PCR with Sp1 primers: 5 0 -TAGCAACTCCAGGCTA-GAGG-3 0 and 5 0 -AACTGACTTCCGCAAGCTCACA-3 0 . The PCR conditions were 94°C for 1 min, 56°C for 2 min and 72°C for 2 min. The amplification products obtained in 30 cycles were analyzed in a 2% agarose gel and visualized by ethidium bromide staining.
Three-dimensional spheroid cultures MCF7 cells were plated in single-cell suspension in 2% agar-coated plates and left untreated or treated with 1 lM OHT or 100 ng/ml EGF for 48 h. To block E-cadherin function, the medium was supplemented with E-cadherin antibody (1:100 dilution; Chemicon International, Temecula, CA) or EGTA to a final concentration of 4 mM. To generate three-dimensional spheroids, the plates were rotated for 4 h at 37°C. The three-dimensional cultures were photographed using a phase-contrast microscope (Olympus, Sun Valley, CA). The extent of aggregation was scored by measuring the spheroids with an ocular micrometer. The spheroids between 25 and 50, 50 and 100, and [100 lm (in the smallest cross-section) were counted in 10 different fields under 109 magnification.
Statistical analysis
Statistical analysis was performed using ANOVA, followed by Newman-Keuls testing to determine differences in means.
Results
OHT and EGF transactivate the E-cadherin promoter and induce E-cadherin mRNA and protein expression
On the basis of our previous study, demonstrating that E-cadherin expression is induced by E 2 [35] and considering the potential of OHT and EGF to exert agonist activity through ERa, we evaluated whether these compounds could regulate E-cadherin expression like E 2 . An expression vector containing the human E-cadherin promoter was transactivated by OHT and EGF in MCF7 cells (Fig. 1a) . Treating cells with OHT in combination with EGF, the transcriptional response was similar using each compound alone (Fig. 1a) . In line with these findings, OHT and EGF induced E-cadherin mRNA expression at the same extent treating cells with both compounds (Fig. 1b, c) . Then, we Fig. 1 OHT and EGF transactivate the E-cadherin promoter and increase E-cadherin mRNA expression. a MCF7 cells were transiently transfected with a luciferase reporter plasmid containing the full-length human E-cadherin promoter p-1008/?49 and treated with 1 lM OHT, 100 ng/ml EGF or a combination of both compounds. The luciferase activities were normalized to the internal transfection control. Each data point represents the mean ± SD of three independent experiments performed in triplicate. b The expression of E-cadherin was evaluated by semiquantitative RT-PCR in MCF7 cells treated with 1 lM OHT, 100 ng/ml EGF or a combination of both compounds for 16 h; 36B4 levels were determined as a control. c The quantitative representation of data (mean ± SD) of three independent experiments. * indicates P \ 0.05 for cells receiving vehicle (-) versus treatments Breast Cancer Res Treat (2010) 121:79-89 81 explored whether the agonistic effect displayed by OHT in upregulating E-cadherin expression was also evident in the modulation of the classical estrogen target gene pS2. Hence, MCF7 cells were treated with E 2 , OHT and the combination of both compounds and EGF. The upregulation of pS2 by E 2 was abolished by OHT (Fig. 2a, b) , confirming that OHT can act as a mixed agonist-antagonist depending on the gene response evaluated. Moreover, EGF was also able to upregulate pS2 mRNA expression (Fig. 2a, b) . Thereafter, we asked whether OHT and EGF could upregulate E-cadherin expression at the protein level. Upon exposure to each compound or a combination of both, we observed an increase in E-cadherin protein levels, which was prevented by the ER antagonist ICI, the Src and ERK inhibitors PP2 and PD, respectively ( Fig. 3a-d) . The latter findings showing the involvement of the MAPK pathway was also confirmed by the ability of OHT and EGF to trigger a rapid ERK1/2 phosphorylation similar to that observed upon E 2 exposure (Fig. 4) . Taken together, these results suggest that both OHT and EGF involve ERa as well as Src and MAPK signaling in the regulation of E-cadherin expression.
ERa and EGFR silencing abrogates the E-cadherin upregulation by OHT and EGF
The results obtained prompted us to define the role exerted by ERa and EGFR in mediating E-cadherin stimulation by both OHT and EGF. Interestingly, after knocking down ERa expression, neither OHT nor EGF was able to upregulate E-cadherin expression (Fig. 5a, b) confirming the data obtained using the ER antagonist ICI. Moreover, EGFR silencing also resulted in the abrogation of the E-cadherin increase upon exposure to each compound (Fig. 5c, d ). The role of EGFR signaling was further ascertained observing an upregulation of EGFR protein expression particularly treating MCF7 cells with OHT (Fig. 5e ). These results suggest that a functional cross-talk between ERa and EGFR triggers E-cadherin expression by the agents used.
OHT and EGF induce the recruitment of ERa to the Sp1 site located within the E-cadherin promoter sequence
The interaction of ERa with the E-cadherin promoter sequence was investigated using ChIP assay. To this end, the MCF7 chromatin was immunoprecipitated with antiERa or anti-RNA Pol II antibodies. PCR was used to determine the recruitment of ERa to the E-cadherin region containing the Sp1 site (-144/-132 nt). Interestingly, the weak ERa recruitment to the E-cadherin promoter observed in cells treated with vehicle increased upon OHT and EGF treatment (Fig. 6a) . In addition, both compounds induced the recruitment of RNA Pol II indicating the ability to stimulate E-cadherin transcription (Fig. 6a) . Next, the E-cadherin protein increase stimulated by OHT and EGF was no longer evident silencing Sp1 in MCF7 cells (Fig. 6b) . A similar result was obtained using mithramycin, an inhibitor of Sp1-DNA interactions (Fig. 6c) . These data confirm the role exerted by the Sp1 site in mediating the upregulation of E-cadherin upon OHT and EGF treatments.
OHT and EGF induce MCF7 cell-cell adhesion in three-dimensional cultures
On the basis of our previous study, showing that the increase in E-cadherin expression by E 2 is responsible for enhanced MCF7 cell aggregation [35] , we evaluated whether OHT and EGF could induce the same effect. Considering that multicellular spheroid cultures can closely reproduce some biologic features of tumors and improve the relevance of results obtained by in vitro studies Fig. 2 OHT acts as an agonist for E-cadherin mRNA expression but as an antagonist for pS2 mRNA expression. a The expression of E-cadherin and pS2 was evaluated by semiquantitative RT-PCR in MCF7 cells treated with 1 lM OHT, 100 nM E 2 , a combination of both compounds and 100 ng/ml EGF for 16 h; 36B4 levels were determined as a control. b The quantitative representation of data (mean ± SD) of three independent experiments. * indicates P \ 0.05 for cells receiving vehicle (-) versus treatments Fig. 3 Immunoblots of E-cadherin from MCF7 cells. MCF7 cells were exposed for 16 h to 1 lM OHT, 100 ng/ml EGF or a combination of both compounds (a). MCF7 cells were exposed for 16 h to 1 lM OHT and 100 ng/ml EGF alone or in combination with 10 lM ICI 182,780 (b), Src family tyrosine kinase inhibitor PP2 (c), [39-41], we used three-dimensional MCF7 cultures as an experimental model. MCF7 cell-cell adhesion was enhanced following a 48-h exposure to OHT and EGF (Fig. 7) , which both induced the formation of spheroids prevalently with a diameter greater than 50 lm (Table 1) . Moreover, supplementing the culture medium with function-blocking E-cadherin antibody or the calcium-chelating agent EGTA, we verified the direct involvement of E-cadherin in the enhanced cell-cell adhesion upon OHT and EGF treatments. In the presence of the E-cadherin antibody, the MCF7 cells showed the formation of small aggregates and limited intercellular contact, whereas in the presence of EGTA MCF7 cells remained rounded and separately suspended (Fig. 7) .
Discussion
Estrogens play a major role in the development of breast cancer. Nearly, 70% of breast tumors express the ERa that allows for the use of antiestrogen therapy as a reliable therapeutic approach for all stages of the disease [42] . The ER antagonist tamoxifen has been shown to improve the survival in early breast cancer [43] as well as the quality of life in patients with metastatic disease [13] . Despite the documented benefits of ER-targeted therapy in breast cancer, approximately 50% of patients with advanced disease do not respond to first-line treatment with tamoxifen due to de novo or intrinsic resistance. Furthermore, almost all patients with metastatic disease and many who receive tamoxifen as adjuvant therapy eventually experience tumor relapse (acquired resistance). Thus, tamoxifen resistance occurs frequently in breast cancer patients and seriously limits treatment efficacy [42, 44] . Multiple mechanisms have been proposed to contribute to the failure of tamoxifen therapy, including changes in the uptake or metabolism of tamoxifen, presence of ER mutants and ligand-independent ER activation, loss of expression of ER and/or cofactors, and modification of the estrogen response element [42, 45] . A large body of clinical and experimental studies has suggested that alteration of ER function by growth factor pathways may be involved in tamoxifen resistance [14, 42, [46] [47] [48] . In this context, it has been reported that phosphorylation of ERa by EGFR-mediated signaling enhances the estrogen-induced transcriptional activity [49, 50] . An increased recruitment of coactivators, such as AIB1 [51] , and conformational changes [52] after receptor phosphorylation also contribute to enhanced transcriptional activity of ERa in tamoxifen-resistant breast cancer cells. In addition, an inverse relationship between the expression of ERa and EGFR or c-erbB2 was observed in primary breast cancer samples and was associated with decreased sensitivity to endocrine therapy and a poorer prognosis [47, 53] . Hormone-dependent breast cancer cells engineered to overexpress EGFR and c-erbB2 resulted in stimulated hormone-independent cell growth [54, 55] .
Our present data demonstrate that EGF enhances E-cadherin expression and promotes homotypic aggregation of breast cancer cells maintained as three-dimensional cultures. Fig. 7 OHT and EGF induce cell-cell adhesion in three-dimensional cultures. E-cadherin-positive MCF7 cells were seeded in 2% agarcoated plates and cultured as three-dimensional spheroids. To block E-cadherin function, the medium was supplemented with E-cadherin antibody (1:100 dilution; a-E-cad) or EGTA (4 mM). Cells were untreated or treated with 1 lM OHT or 100 ng/ml EGF for 48 h and then photographed under phase-contrast microscopy. Bar, 50 lm E-cadherin is an intercellular adhesion molecule generally implicated as tumor suppressor in several types of epithelial tumors, based on findings that the expression of this homotypic adhesion molecule is frequently lost in human epithelial cancers [29] [30] [31] . However, it has well been shown in ovarian epithelial tumors that E-cadherin expression is much more elevated than normal ovaries, suggesting that E-cadherin can play a role in the development of ovarian carcinomas [56] . For instance, it is worth to mention that not only E-cadherin may serve as an intercellular adhesion molecule, but it may also trigger intracellular activation of proliferation and survival signals [35, 57] . Our recent findings provided evidence that E 2 may be involved in mammary tumorigenesis on the basis of its stimulatory effects on primary tumor mass either in vivo using MCF7 cell tumor xenograft or in vitro using MCF7 three-dimensional cultures [35] . These actions were elicited by E 2 through homotypic tumor cell adhesion consequent to an increase in E-cadherin expression [35] .
A number of studies have evaluated the usefulness of E-cadherin expression with respect to survival of breast cancer patients. Several studies indicate that reduced E-cadherin expression is an independent indicator of poor survival, particularly in node-negative patients [58] [59] [60] [61] . However, other studies have found E-cadherin to be of little use in predicting clinical behavior of breast cancer patients [62] . Indeed, one study even noted that strong E-cadherin immunostaining correlated with poor survival [63] . In short, currently there are conflicting opinions about the prognostic value of altered E-cadherin expression. Thus, the usefulness of E-cadherin as a predictor of clinical behavior for breast cancer patients is still under debate.
In the present study, we showed that a cross-talk between ERa and EGFR was involved in E-cadherin expression by both OHT and EGF as demonstrated using the pure ER antagonist ICI, the Src and ERK inhibitors PP2 and PD, respectively, and most importantly silencing either ERa or EGFR expression. Moreover, OHT and EGF stimulated ERa recruitment to the Sp1 site within the E-cadherin promoter region, whereas, blocking this site either by silencing Sp1 or using mithramycin, ERa binding to the E-cadherin promoter region was no longer evident.
Thus, in conclusion, we provide further insights into the molecular mechanisms involved in the agonist activity exerted by tamoxifen in breast cancer, through the evidence that OHT per se is able to activate the promoter of E-cadherin, increasing E-cadherin expression at the mRNA and protein levels and thus may enhance homotypic aggregation of MCF7 breast cancer cells.
In addition, we have demonstrated that E-cadherin is a target of a cross-talk between EGF and OHT/ER signaling, since the upregulatory effect induced by OHT on E-cadherin expression was abrogated in the presence of either ERa or EGFR silencing. It is worth to note that in our experimental conditions tamoxifen induced an enhanced expression of EGFR protein levels, which may contribute to the failure of adjuvant endocrine therapy in breast cancer, as suggested by a growing body of data. The latter observations highlight how the agonistic effect of tamoxifen and EGF may sustains tumor mass growth through cell-cell aggregation.
